Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ADH1B | P00325 | 1/20 | 0.45 |
| ▸ | ADH1C | P00326 | 1/20 | 0.45 |
| ▸ | ADH1A | P07327 | 1/20 | 0.45 |
| ▸ | ADH4 | P08319 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25009603 | 1.00 | EPHX1 (0.61) | EPHX1CA12CA1CA2MMP1 | |
| SCHEMBL20125204 | 1.00 | EPHX1 (0.61) | EPHX1CA12CA1CA2MMP1 | |
| SCHEMBL1434420 | 1.00 | EPHX1 (0.61) | EPHX1CA12CA1CA2MMP1 | |
| SCHEMBL5968680 | 0.98 | EPHX1 (0.57) | EPHX1CA12CA1CA2MMP1 | |
| Bicarbonate SCHEMBL5722423 | 0.93 | EPHX1 (0.53) | EPHX1CA12CA1CA2MMP1 | |
| SCHEMBL5969117 | 0.93 | — | — | |
| SCHEMBL48633 | 0.88 | — | — | |
| SCHEMBL13165688 | 0.88 | TDP1 (0.58) | EPHX1CA12CA1CA2MMP1 | |
| Hydrochloric Acid SCHEMBL4553435 | 0.86 | — | — | |
| SCHEMBL1898034 | 0.84 | NPC1 (0.44) | EPHX1CA12CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | claimed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | claimed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | claimed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-9315454-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| EP-2429993-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-8841331-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841331-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8497380-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2013-07-30 | — | — | US | disclosed |
| US-20130012716-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | FELDING JAKOB (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | disclosed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | disclosed |
| EP-1727789-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | Pfizer Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005090287-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3B | EPHX1 634/4885CA12 2438/4885CA1 1828/4885 |
| US-20130012716-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE3B, PDE5A | EPHX1 694/4885CA12 2139/4885CA1 1584/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | EPHX1 1958/4885CA12 2427/4885CA1 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.